Nonprescription Statins: Not Ready for Prime Time

American Journal of Cardiology

Volumn 101, Issue 5, 2008, Pages 745-746

  Whayne Jr , Thomas F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NON PRESCRIPTION DRUG; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; FAMILY HISTORY; HEPATITIS; HUMAN; LETTER; MYALGIA; MYOPATHY; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SMOKING; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; MUSCLE DISEASE; NOTE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PARTICIPATION; PRIMARY PREVENTION; SAFETY;

CORONARY DISEASE; DRUGS, NON-PRESCRIPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PRIMARY PREVENTION; RISK ASSESSMENT; SAFETY;

EID: 41949093962     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.09.112     Document Type: Letter

References (10)

1. Fuster V. A new perspective on nonprescription statins: an opportunity for patient education and involvement. Am J Cardiol 100 (2007) 907-910
2. Sica D. Over-the counter statin therapy-pros and cons. J Clin Hypertens 7 (2005) 262-299
3. Cannon C., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
4. LaRosa J., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
5. Staffa J., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
6. Thompson P., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
7. Phillips P., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., and England J.D. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
8. Hansen K., Hildebrand J.P., Ferguson E.E., and Stein J.H. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165 (2005) 2671-2676
9. Hyre A., Krousel-Wood M.A., Muntner P., Kawasake L., and DeSalvo K.B. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens 9 (2007) 179-186
10. Rosenson R. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416